QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

SRPT

QT74Sarepta Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
17.53
+0.57+3.36%
OverviewShort InterestFilings
SRPTQT74Sarepta Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
17.53+3.36%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E28.11EPS (ttm)
-0.96
Insider Own5.56%
Shs Outstand105.58M
Perf Week16.87%
Market Cap1.79BForward P/E17.95EPS next Y0.98Insider Trans0.08%Shs Float-Perf Month5.35%
Enterprise Value2.41BPEG0.06EPS next Q0.21Inst Own-Short Float-Perf Quarter5.29%
Income65.47MP/S0.84EPS this Y467.23%Inst Trans-Short Ratio-Perf Half Y-21.43%
Sales2.18BP/B1.22EPS next Y-72.30%ROA2.05%Short Interest-Perf YTD-18.54%
Book/sh14.25P/C10.43EPS next 5Y-44.20%ROE4.89%52W High25.32 -30.77%Perf Year-18.69%
Cash/sh6.18P/FCF17.33EPS past 3/5Y-ROIC-1.53%52W Low10.42 68.23%Perf 3Y-
Dividend Est.-EV/EBITDA19.30Sales past 3/5Y33.06% 32.41%Gross Margin62.39%Volatility4.21% 3.40%Perf 5Y-
Dividend TTM-EV/Sales1.10EPS Y/Y TTM-37.18%Oper. Margin-1.88%ATR (14)0.92Perf 10Y-
Dividend Ex-Date-Quick Ratio2.62Sales Y/Y TTM14.83%Profit Margin2.98%RSI (14)53.94Recom2.83
Dividend Gr. 3/5Y-Current Ratio4.63EPS Q/Q192.40%SMA206.99%Beta2.30Target Price25.14
Payout0.00%Debt/Eq0.69Sales Q/Q-1.88%SMA50-6.76%Rel Volume1.93Prev Close16.96
Employees1,372LT Debt/Eq0.90EarningsAug 05SMA200-11.11%Avg Volume2.91MPrice17.53
IPO DateJun 04, 1997Option/ShortYes / YesEPS/Sales Surpr.223.77% 54.22%Net Debt/EBITDA4.58Volume5,608,683Change3.36%
Analyst Ratings
DateActionAnalystRatingTarget
May-15-26ReiteratedEvercore ISI$20 → $19
Mar-26-26ReiteratedDeutsche BankSell$12 → $14
Mar-26-26ReiteratedWedbushOutperform$29 → $35
Mar-12-26ReiteratedMizuho Securities$26 → $31
Mar-03-26ReiteratedLoop Capital Markets$25
Mar-03-26ReiteratedJefferiesBuy$165 → $30
Jan-27-26ReiteratedRobert W. Baird$15 → $22
Dec-09-25InitiatedWedbushOutperform$32
Nov-25-25ReiteratedBernsteinOutperform$18 → $20
Nov-05-25ReiteratedMizuho Securities$200 → $26
Latest News
Jun-17-26
Jun-17-2601:33PM
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market TodayBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,1842,1981,902
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A822882319
Gross Profit1,3631,3171,583
Selling, General and Administrative Excl. Other467479558
Research and Development9021,522805
Other Operating Expense35-262
Operating Income-41-658218
Interest Expense431018
Unusual Expense
———
Non-Operating Income (Expense)-12035-61
Net Income Before Taxes25-702261
Income Taxes-401126
Consolidated Net Income65-713235
Net Income From Continuing Operations65-713235
Net Income65-713235
EPS (Recurring)0.62-7.132.47
EPS (Basic, Before Extraordinaries)0.62-7.132.47
EPS (Diluted)-0.96-7.132.34
EBITDA125-648317
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio0.841.03—
Gross Margin62.4159.9283.23
Operating Margin-1.88-29.9411.46
Net Margin2.98-32.4412.36
Shares Outstanding10510595
Market Capitalization1,8412,260—
Operating Lease Expense
———
Insider Trading Volume
$18.82$17.35$15.89$14.43$12.96● Close Price0.00K73.55K147.10K220.65K294.20KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Mayo StephenDirectorMar 12 '26Sale17.027,239123,2081,765Mar 13 12:00 AM
Rodino-Klapac LouisePresident, R&D and Tech OpsMar 01 '26Option Exercise0.0016,2500232,155Mar 03 12:00 AM
Estepan Ian MichaelChief Operating OfficerMar 01 '26Option Exercise0.0016,2500208,875Mar 03 12:00 AM
Estepan Ian MichaelChief Operating OfficerFeb 26 '26Option Exercise13.7112,831175,914200,750Mar 02 12:00 AM
Nicaise ClaudeDirectorJan 29 '26Option Exercise13.7121,000287,91038,312Jan 29 12:00 AM
BEHRENS M KATHLEENDirectorJan 27 '26Option Exercise13.7121,000287,910203,976Jan 29 12:00 AM
Estepan Ian MichaelChief Operating OfficerDec 16 '25Sale22.3113,187294,202193,300Dec 18 12:00 AM
Barry RichardDirectorMay 16 '25Option Exercise32.6324,700805,9622,966,667May 19 12:00 AM
Barry RichardDirectorMay 13 '25Option Exercise19.2340,492778,7182,954,317May 15 12:00 AM
Nicaise ClaudeDirectorMar 12 '25Option Exercise25.1819,492490,80830,303Mar 13 12:00 AM
Nicaise ClaudeDirectorMar 12 '25Sale99.642,491248,20327,812Mar 13 12:00 AM
Murray DallanChief Customer OfficerMar 07 '25Option Exercise0.0011,000033,659Mar 11 12:00 AM
Estepan Ian MichaelChief Financial OfficerMar 07 '25Option Exercise0.0011,000058,277Mar 11 12:00 AM
Rodino-Klapac LouiseHead of R&D, CSOMar 07 '25Option Exercise0.0011,000079,818Mar 11 12:00 AM
Murray DallanChief Customer OfficerMar 06 '25Option Exercise0.0035,000037,321Mar 10 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR